A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 204 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... March 27, 2019 Cancer Survivor And His Organ Donor Run NYC Marathon Together To... November 7, 2021 BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... August 11, 2020 What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 Load more HOT NEWS Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in... Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... Marine Runs Five Marathons in Five Days to Help Fund Sister’s...
